{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:05Z","timestamp":1763017805228,"version":"3.44.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ahj.2017.08.016","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T11:00:56Z","timestamp":1503486056000},"page":"49-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Atrial fibrillation decision support tool: Population perspective"],"prefix":"10.1016","volume":"194","author":[{"given":"Mark H.","family":"Eckman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Costea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehran","family":"Attari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitender","family":"Munjal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth E.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Knochelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew L.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pete","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ireton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett M.","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony C.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Steen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2017.08.016_bb0005","first-page":"302","article-title":"The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective","volume":"19","author":"Casciano","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.ahj.2017.08.016_bb0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2017.08.016_bb0015","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2017.08.016_bb0020","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2017.08.016_bb0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2017.08.016_bb0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2017.08.016_bb0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2016.02.009","article-title":"Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation","volume":"176","author":"Eckman","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2017.08.016_bb0040","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.114.001163","article-title":"Integrating real-time clinical information to provide estimates of net clinical benefit of antithrombotic therapy for patients with atrial fibrillation","volume":"7","author":"Eckman","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2017.08.016_bb0045","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jgs.14099","article-title":"Using an Atrial Fibrillation Decision Support Tool for thromboprophylaxis in atrial fibrillation: effect of sex and age","volume":"64","author":"Eckman","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ahj.2017.08.016_bb0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1185\/03007995.2015.1019608","article-title":"Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making","volume":"31","author":"Eckman","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ahj.2017.08.016_bb0055","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2017.08.016_bb0060","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2017.08.016_bb0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2017.08.016_bb0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2017.08.016_bb0075","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2017.08.016_bb0080","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","article-title":"Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review","volume":"157","author":"Adam","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0085","doi-asserted-by":"crossref","first-page":"640723","DOI":"10.1155\/2013\/640723","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups","volume":"2013","author":"Gomez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"10.1016\/j.ahj.2017.08.016_bb0090","first-page":"93","article-title":"Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation","volume":"8","author":"Tawfik","year":"2016","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.ahj.2017.08.016_bb0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.beha.2013.07.011","article-title":"New oral anticoagulants in elderly patients","volume":"26","author":"Barco","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ahj.2017.08.016_bb0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jgs.12799","article-title":"New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials","volume":"62","author":"Sardar","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ahj.2017.08.016_bb0105","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort","volume":"41","author":"Lip","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2017.08.016_bb0110","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2017.08.016_bb0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1160\/TH08-09-0592","article-title":"Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention","volume":"101","author":"Poli","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2017.08.016_bb0120","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/STROKEAHA.108.526988","article-title":"Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators","volume":"40","author":"van Walraven","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2017.08.016_bb0125","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0135","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1532-5415.2006.00828.x","article-title":"Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study","volume":"54","author":"Fang","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ahj.2017.08.016_bb0140","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0145","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1161\/01.STR.0000174189.81153.85","article-title":"Risk of hemorrhagic stroke with aspirin use: an update","volume":"36","author":"Gorelick","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2017.08.016_bb0150","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jama.280.22.1930","article-title":"Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials","volume":"280","author":"He","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2017.08.016_bb0155","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"author":"Arias","key":"10.1016\/j.ahj.2017.08.016_bb0160"},{"key":"10.1016\/j.ahj.2017.08.016_bb0165","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/j.ajkd.2012.08.001","article-title":"GFR estimation using the Cockcroft-Gault, MDRD study, and CKD-EPI equations in the elderly","volume":"60","author":"Flamant","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2017.08.016_bb0170","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2017.08.016_bb0175","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2017.08.016_bb0180","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/CIRCULATIONAHA.116.024057","article-title":"Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation","volume":"135","author":"Quinn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2017.08.016_bb0185","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2007.09.065","article-title":"Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation","volume":"51","author":"Fang","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2017.08.016_bb0190","doi-asserted-by":"crossref","first-page":"1410-6","DOI":"10.1161\/STROKEAHA.108.526988","article-title":"Effect of age on stroke prevention therapy in patients with atrial fibrillation. The Atrial Fibrillation Investigators","volume":"40","author":"van Walraven","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2017.08.016_bb0195","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/archinte.165.10.1185","article-title":"Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study","volume":"165","author":"Sherman","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0200","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0002-9343(02)01063-X","article-title":"Stroke severity in patients with atrial fibrillation","volume":"112","author":"Penado","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0205","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archneur.1982.00510140003001","article-title":"Subdural hematoma and oral anticoagulant therapy","volume":"39","author":"Wintzen","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ahj.2017.08.016_bb0210","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.410160505","article-title":"The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study","volume":"16","author":"Wintzen","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ahj.2017.08.016_bb0215","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.STR.26.8.1471","article-title":"Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses","volume":"26","author":"Hart","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2017.08.016_bb0220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archinte.1996.00440040081009","volume":"156","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0225","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0230","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0235","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0240","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/archinte.1996.00440150083009","article-title":"The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life","volume":"156","author":"Gage","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0245","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1161\/01.STR.26.11.2011","article-title":"Prognosis for survival after an initial stroke","volume":"26","author":"Lai","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2017.08.016_bb0250","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess mortality among persons with type 2 diabetes","volume":"373","author":"Tancredi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0255","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2017.08.016_bb0260","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/hs0901.094253","article-title":"Long-term survival and causes of death after stroke","volume":"32","author":"Bronnum-Hansen","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2017.08.016_bb0265","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2017.08.016_bb0270","first-page":"e46","article-title":"Heart disease and stroke statistics\u20142010 update: a report from the American Heart Association","volume":"121","author":"Writing Group M","year":"2010","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317302466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317302466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:59:47Z","timestamp":1757570387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317302466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":54,"alternative-id":["S0002870317302466"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.08.016","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial fibrillation decision support tool: Population perspective","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}